An observational study in Chronic Limb Ischemia, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.
Sponsored by University Hospital, Strasbourg, France · Observational
The femoro-popliteal arterial segment is one of the most frequent locations for atherosclerosis. Its management is mainly endovascular (standard and coated-balloon angioplasty, stenting).
However, the structural features of the atherosclerotic disease in regards to patient's risk factors and past medical and surgical histories are not well studied. Furthermore, the histological analysis of the femoro-popliteal arterial segment is rare in the literature, and made difficult mostly because of the length of this segment.
There is a clinical need for better understanding of atherosclerotic lesions in this location, with as further goal, a better management of this disease.
University Hospital, Strasbourg, France is the lead sponsor of 997 studies on the registry; 356 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with chronic limb ischemia that are scheduled for transfemoral amputation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Explantation of the femoro-popliteal arterial segment from the amputed limb
Descriptive analysis of the arterial structure in micro-CT.
study precisely the pathological structure of the femoro-popliteal arterial segment in AOMI, both in imaging and histologically.
Time frame: 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →